IICS4all 2027 supports investigators conducting inclusive multinational clinical trials to compare existing interventions or repurpose off-patent drugs across four chronic disease areas to address patient needs.
Investigator Initiated Studies (IIS) supports scientists and clinical researchers pursuing independent clinical, observational, and outcomes research to explore questions or develop new treatment concepts.
Innovative healthcare interventions for non-communicable diseases supports research consortia testing treatments in early-stage clinical trials to improve management of cardiovascular, metabolic, lung and kidney diseases.
Investigator-Initiated Research (IIR) supports independent investigators with funding, study drug, or data and samples for research addressing unmet patient needs or important scientific questions.
Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers supports cancer infrastructures to study diagnosis and treatment and improve access to care.
Ionis Pharmaceuticals' Investigator‑Initiated Research Program funds independent studies advancing science in cardiovascular, hereditary angioedema, and neurological diseases.